Apyx Medical (NASDAQ:APYX) Releases Earnings Results, Beats Expectations By $0.03 EPS

Apyx Medical (NASDAQ:APYX) announced its quarterly earnings data on Tuesday. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.03, FiscalAI reports. The firm had revenue of $19.16 million for the quarter, compared to analyst estimates of $19.12 million. Apyx Medical had a negative return on equity of 139.09% and a negative net margin of 21.22%.

Here are the key takeaways from Apyx Medical’s conference call:

• Reported a record fourth-quarter revenue of $19.2 million (up 35% YoY), driven by a 38% increase in surgical aesthetics sales to $16.7M following the full commercial launch of AYON.
• Management says AYON demand has exceeded expectations and they submitted a follow-up 510(k) for power-assisted liposuction with productive FDA discussions and an anticipated clearance in mid-2026, which can be activated on systems already in the field.
• 2026 guidance targets total revenue of $57.5–$58.5 million (≈9–11% growth) with surgical aesthetics up ~17–19%, but OEM revenue is expected to decline to about $4.5M as the company reallocates resources toward aesthetics.
• Profitability and cash metrics improved — Q4 adjusted EBITDA was positive $0.7M, net loss narrowed to $1.3M, cash was $31.7M at year-end, and management expects cash runway through 2027 and to be cash-flow positive by Q4 2026.

Apyx Medical Stock Up 13.9%

Apyx Medical stock opened at $3.93 on Thursday. The company has a debt-to-equity ratio of 5.69, a quick ratio of 3.61 and a current ratio of 4.44. The firm has a market capitalization of $150.29 million, a price-to-earnings ratio of -14.56 and a beta of 1.61. Apyx Medical has a fifty-two week low of $0.76 and a fifty-two week high of $4.50. The stock’s fifty day moving average is $3.75 and its two-hundred day moving average is $3.31.

Apyx Medical News Roundup

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Craig Hallum raised its price target to $6.00 and initiated/maintained a “buy” view, implying ~52.7% upside from recent levels — a catalyst for bullish investor sentiment. Article Title Article Title
• Positive Sentiment: BTIG upgraded APYX from Neutral to Buy and set a $6.00 target, reinforcing the positive analyst momentum. Article Title Article Title
• Positive Sentiment: Q4 results slightly beat expectations: EPS of ($0.03) vs. consensus ($0.06) and revenue of $19.16M vs. $19.12M — the beat and management commentary (record revenue / strategic growth) support the upgrade momentum. Article Title Press Release
• Positive Sentiment: Management raised FY2026 revenue guidance to $57.5M–$58.5M vs. street ~$55.9M and outlined a 9%–11% revenue growth target as AYON rollout accelerates — suggests better topline visibility into 2026. Press Release Article Title
• Neutral Sentiment: Analyst coverage and press summaries (earnings breakdowns and call highlights) are amplifying the story for investors but mostly restate the beats/guidance. Article Title
• Negative Sentiment: Short interest has shown increases earlier in the period (Feb short interest ~173,573 shares, +22.3%), and the company still posts negative margins and ROE — these remain downside risks if execution lags. (March short-interest data appears inconsistent/zero in some reports and may reflect a reporting anomaly.)

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wall Street Zen upgraded shares of Apyx Medical to a “hold” rating in a research report on Saturday, November 22nd. Citizens Jmp upgraded shares of Apyx Medical from a “market perform” rating to an “outperform” rating and set a $8.00 price objective for the company in a research note on Wednesday, November 12th. Craig Hallum boosted their price objective on shares of Apyx Medical from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday. Roth Mkm assumed coverage on shares of Apyx Medical in a research report on Monday, December 15th. They set a “buy” rating and a $6.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apyx Medical in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.50.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Nantahala Capital Management LLC increased its stake in Apyx Medical by 19.1% during the fourth quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock worth $13,909,000 after acquiring an additional 636,043 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Apyx Medical by 3.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock worth $3,272,000 after purchasing an additional 53,175 shares during the period. Geode Capital Management LLC increased its position in Apyx Medical by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 358,829 shares of the company’s stock worth $1,257,000 after purchasing an additional 7,551 shares in the last quarter. Informed Momentum Co LLC acquired a new position in Apyx Medical during the fourth quarter valued at approximately $863,000. Finally, 683 Capital Management LLC purchased a new stake in Apyx Medical during the fourth quarter worth approximately $436,000. 55.33% of the stock is owned by hedge funds and other institutional investors.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.